 CELEBRATION, Fla., Dec. 23, 2020 GLOBE NEWSWIRE -- KemPharm, Inc. OTCQB: KMPH, a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Companys Board of Directors has approved a 1-for-16 reverse stock split of its shares of common stock Reverse Stock Split. KemPharms stockholders granted authority to the Board of Directors to effect this Reverse Stock Split of KemPharms common stock at the Special Meeting of Stockholders held on November 17, 2020. The Reverse Stock Split is intended to enable the Company to potentially regain its listing on the Nasdaq Capital Market. 